Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as XS-04 tablet
XS-04 · 1 trial · 3 indications
Safety indicators
Safety indicators and efficacy indicators
| Arm | Type | Description |
|---|---|---|
| A multicenter, open-label, single-arm Phase I dose-escalation and dose-expansion clinical study | EXPERIMENTAL | For drugs, use the generic name and include dosage form, dosage, frequency, and duration. Note: Group description not yet entered.\] XS-04 tablet specifications: 0.5 mg, 5 mg, 20 mg. Dose escalation phase: 1 mg, 3 mg, 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, 160 mg/day (dose adjustment allowed based on actual escalation situation); Cycle 0 phase, oral administration once (dose is half of the total daily dose for the respective dose group), observe for two days (based on the PK results of the first 1-2 dose groups, decide whether the remaining dose groups need Cycle 0 phase); thereafter Cycle 1-N phase, each 28 days is one treatment cycle, continuous administration, two times daily. Dose regimen adjustments are allowed based on PK, safety, and efficacy data in this trial. Dose expansion phase: Based on the results of the dose escalation phase, cohort one and cohort two are planned to use the RP2D dose, cohort three safety lead-in phase is |
| Name | Type | Description |
|---|---|---|
| XS-04 tablet | DRUG | Each treatment cycle is 28 days, with continuous oral administration, twice daily. |
Inclusion Criteria Patients must meet all of the following conditions to be enrolled: * Voluntarily participate in the clinical trial and sign the informed consent form (ICF). * Age ≥18 years, ≤75 years, regardless of gender. * Dose escalation phase: Patients with mature B-cell malignant tumors co...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
XS-04 is an investigational small molecule being developed for the treatment of B-cell Lymphoma. It is also being studied in patients with relapsed or refractory hematologic malignancies, including Acute Myeloid Leukemia and Myelodysplastic Syndrome. The drug is currently in Phase 1 clinical development.
XS-04 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The company is conducting a Phase 1 clinical trial of XS-04 in patients with relapsed or refractory hematologic malignancies.
XS-04 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in patients with B-cell Lymphoma and other hematologic malignancies.
XS-04 is being studied in a Phase 1 clinical trial with the identifier NCT06820268. This trial is titled 'A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies' and is currently recruiting participants in China. The study is an uncontrolled, open-label trial with an enrollment target of 168 patients.
Yes, XS-04 is also known as XS-04 tablet. The drug is being developed as an oral tablet formulation for the treatment of B-cell Lymphoma and other hematologic malignancies.
The Phase 1 clinical trial of XS-04 (NCT06820268) is studying the drug in patients with B-cell Lymphoma, Acute Myeloid Leukemia, and Myelodysplastic Syndrome. The trial is enrolling adults aged 18 years and older of all sexes in China.